

# Thoracic Disease-Oriented Team

---

Clinical Research Treatment Flowchart

## ADVANCED/METASTATIC

■ Open to Accrual

■ Low Accruing

■ Pending Activation

1L

### UCI 24-192 (Nuvalent)

NVL-655 vs Alectinib

Mechanism: ALK inhibitor  
Coord: Mindy Chen  
PI: Dr. Nagasaka  
Accrual: 2/5

2L

### UCI 21-241 (Nuvalent)

NVL-655 + ALK inhibitor

Mechanism: ALK Inhibitor  
Coord: Keagan Buttigieg  
PI: Dr. Nagasaka  
Accrual: 20/25

### UCI 25-51 (Nuvalent)

NVL-655 EAP

Mechanism: ALK inhibitor  
Coord: Mindy Chen  
PI: Dr. Park  
Accrual: 22/30

### UCI 25-189 (Astellas)

Mechanism: ALK inhibitor  
Coord: Richard Chang  
PI: Dr. Arter  
Accrual: 3/5

### UCI 26-23 (Triana Biomedicines)

Mechanism: ALK inhibitor  
Coord: To be determined  
PI: Dr. Nagasaka  
Accrual: 0/10

### UCI 26-38 (Chugai Pharmaceutical)

AQUA07 +/- Lorlatinib

Mechanism: ALK inhibitor  
Coord: To be determined  
PI: Dr. Nagasaka  
Accrual: 0/5

Exon 18

Exon 19 del or L858R

1L

**UCI 24-169 (BlossomHill Therapeutics)**  
BH-30643 Capsule

Mechanism: EGFR or HER2 TKI  
Coord: Celest Ramirez  
PI: Dr. Nagasaka  
Accrual: 14/15

**UCI 24-169 (BlossomHill Therapeutics)**  
BH-30643 Capsule

Mechanism: EGFR or HER2 TKI  
Coord: Celest Ramirez  
PI: Dr. Nagasaka  
Accrual: 14/15

**UCI 25-80 (AstraZeneca/TROPION -Lung14)**  
Osimertinib +/- Dato-DXd

Mechanism: TKI +/- ADC  
Coord: Celest Ramirez  
PI: Dr. Nagasaka  
Accrual: 1/5

**UCI 23-178 (Systimmune)**  
BL-B01D1 IV

Mechanism: EGFR and/or HER3 bispecific antibody  
Coord: Cassie Smith  
PI: Dr. Park  
Accrual: 6/10

**UCI 25-187 (BMS/IZABRIGHT-Lung01)**  
Iza-Bren vs platinum based chemo + pemetrexed

Mechanism: ADC  
Coord: Lizbeth Garcia  
PI: Dr. Nagasaka  
Accrual: 1/5

**UCI 26-72 (HUTCHMED)**  
HMPL-A580

Mechanism: EGFR-directed antibody-targeted therapy conjugate (ATTC)  
Coord: TBD  
PI: Dr. Arter  
Accrual: 0/5

**UCI 26-106 (UCLA L-14)**  
Teliso V + Osimertinib

Mechanism: ADC + TKI  
Coord: TBD  
PI: Dr. Arter  
Accrual: 0/999

2L

## Exon 20

## Exon 21

1L

### 24-169 (BlossomHill Therapeutics)

BH-30643 Capsule

Mechanism: EGFR or HER2 TKI  
Coord: Celest Ramirez  
PI: Dr. Nagasaka  
Accrual: 14/15

### UCI 24-169 (BlossomHill Therapeutics)

BH-30643 Capsule

Mechanism: EGFR or HER2 TKI  
Coord: Celest Ramirez  
PI: Dr. Nagasaka  
Accrual: 14/15

2L

## Exon 20 / Uncommon and Compounded Mutations

1L

UCI 26-10 (UCLA/L-13)Zipalertinib with Carboplatin +  
Pemetrexed

Mechanism: TKI + Chemo

Coord: TBD

PI: Dr. Arter

Accrual: 0/5

2L

## ADVANCED/METASTATIC

1L

Exon 18

Exon 19

Exon 20

Exon 21

UCI 24-169 (BlossomHill Therapeutics)

BH-30643 Capsule

Mechanism: EGFR or HER2 TKI

Coord: Celest Ramirez

PI: Dr. Nagasaka

Accrual: 14/15

2L

UCI 23-178

BL-B01D1 IV

Mechanism: EGFR and/or HER3 bispecific antibody

Coord: Cassie Smith

PI: Dr. Park

Accrual: 6/10

## Early Stage

 Open to Accrual Low Accruing Pending Activation**UCI 25-79 (Beamion Lung-3)**

Zongertinib vs SOC  
(Adjuvant therapy)

Mechanism: TKI  
Coord: To be determined  
PI: Dr. Arter  
Accrual: 0/3

## KRAS G12C

## G12A, G12D, G12R, G12S, G12V (Cont.)

1L

**UCI 22-30 (D3S-001-100):**  
D3 Bio

Mechanism: TKI  
Coord: Cassie Smith  
PI: Dr. Nagasaka  
Accrual: 5/8

**UCI 25-88 (Part A:**  
Olomorasib w/ Pembro or  
Placebo w/ Pembro. Part B:  
Durvalumab w/ Pembro or  
Placebo w/ Durvalumab)

Mechanism: TKI and Anti-  
PD-1 / Anti-PD-L1  
Coord: TBD  
PI: Dr. Park  
Accrual: 0/5

**UCI 25-164: Divarasib**  
**+ Pembro vs Pembro +**  
**Pem + Carbo or**  
**Cisplatin**

Mechanism: TKI +  
Immuno + Chemo  
Coord: TBD  
PI: Dr. Nagasaka  
Accrual: 0/5

2L

**UCI 23-116 (RMC-6291**  
**Revolution Medicine)**

Mechanism: TKI  
Coordinator: Richard  
Chang  
PI: Dr. Arter  
Accrual: 1/10

**UCI 25-162: BBO-**  
**8520(The ONKORAS-**  
**101**

Mechanism: TKI  
Coord: TBD  
PI: Dr. Arter  
Accrual: 0/5

**UCI 24-157 (RMC-6236-301)**  
**RMC-6236 vs Docetaxel**

Mechanism: TKI  
Coord: Celest Ramirez  
PI: Dr. Arter  
Accrual: 0/5

**UCI 22-87 (RMC-6236**  
**Revolution Med)**

Mechanism: TKI  
Coordinator: Jenny Choe  
PI: Dr. Arter  
Accrual: 43/50

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

G12C, G12V, G12D

1L

2L

UCI 25-163  
(TBBO11818-101)

Mechanism: TKI  
Coord: Cassie/Keagan  
PI: Dr. Arter  
Accrual: 0/5

ADVANCED/METASTATIC

NTRK 1-3

Open to Accrual

Low Accruing

Pending Activation

1L

2L

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

## ROS1

1L

### UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI  
Coord: Keagan Buttigieg  
PI: Dr. Nagasaka  
Accrual: 11/16

2L

### UCI 26-83 (NVL-520 EAP Nuvalent)

Mechanism: TKI  
Coord: TBD  
PI: Dr. Park  
Accrual: 0/10

## Early Stage

UCI 24-196 (Nuvation)

Taletrectinib vs Placebo post  
complete resection  
(Adjuvant therapy)

Mechanism: ROS1 inhibitor  
Coord: Stephanie Fernandez  
PI: Dr. Arter  
Accrual: 0/5

 Open to Accrual Low Accruing Pending Activation

## Advanced / Metastatic

Open to Accrual
  Low Accruing
  Pending Activation

1L

**UCI 24-83:** CB-NK +  
Atezolizumab

Mechanism: PD-L1  
Coord: TBD  
PI: Dr. Villalona  
Accrual: 0/9

**UCI 25-114:** Ivonescimab vs  
Pembrolizumab (High PD-L1  
Expression (TPS> 50%))

Mechanism: PD-L1  
Coord: Richard Chang  
PI: Dr. Park  
Accrual: 0/5

**UCI 24-195 (Seagen/Pfizer):**  
**PF-08046054/SGN-PDL1V**  
**\*\*NSCLC cohorts closed\*\***

Mechanism: PD-L1  
Coord: Jenny Choe  
PI: Dr. Nagasaka  
Accrual: 0/5

2L

**Therapeutics:** Thymic  
Cancer (Ivonescimab)

Mechanism: PD-L1  
Coord: Cassie Smith  
PI: Dr. Arter  
Accrual: 0/5

**UCI 25-227 (Fortvita**  
**Biologics):** IBI363 +/- SOC  
therapy

Mechanism: PD-L1  
Coord: TBD  
PI: Dr. Arter  
Accrual: 0/5

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 24-197 (TNG456  
Monotherapy & Combo w/  
Abemaciclib)

Mechanism:  
Coord: Cassie Smith  
PI: Dr. Park  
Accrual: 1/5

 Open to Accrual

 Low Accruing

 Pending Activation

## UCI 25-133: (ZG006)

Mechanism: BiTE molecule

Coord: Jenny Choe

PI: Dr. Arter

Accrual: 2/5

 Open to Accrual

 Low Accruing

 Pending Activation

UCI 25-194 (Plexium)

PLX-61639

Mechanism: SMARCA2  
Degradar

Coord: Jenny Choe

PI: Dr. Villalona

Accrual: 0/5

Adjuvant

ADVANCED/METASTATIC

■ Open to Accrual

■ Low Accruing

■ Pending Activation

**UCI 22-86: Gut Microbiome Study**

Mechanism: Fecal Collection  
Coord: Stephanie Fernandez  
PI: Dr. Nagasaka  
Accrual: 13/82

**UCI 24-118 (Keshava IIT): Lung Cancer Family Screening**

Mechanism: NA  
Coord: Stephanie Fernandez/  
Mindy Chen  
PI: Dr. Keshava  
Accrual: 61/1753

**UCI 25-179 (T. Waddington IIT)**  
Optical Coherence Tomography (OCT) w/ Robotic assisted bronch evaluate peripheral nodes

Mechanism: N/A  
CRC: TBD  
PI: Dr. Waddington  
Accrual: 0/10

**UCI 25-191 (Nagasaka IIT)**

Mechanism: N/A  
CRC: TBD  
PI: Dr. Nagasaka  
Accrual: 0/25

**UCI 24-87 (Arter IIT): Methionine-Reduced Diet**

Mechanism: N/A  
CRC: Keagan Buttigieg  
PI: Dr. Arter  
Accrual: 5/25

**UCI 23-155:**

Chatbot for Online Support Groups to Treat Tobacco Addiction

Mechanism: N/A  
CRC: TBD  
PI: Dr. Pechmann  
Accrual: 0/126

## Advanced / Metastatic

1L

UCI 24-113 (BMS-986482)  
Bristol-Myers Squibb

Mechanism: PDL1  
Coord: Natalie Arechiga  
PI: Dr. Chow  
Accrual: 5/10

2L

UCI 24-08 (SPEDOX-6): Dr.  
Chow IIT

Mechanism: SPE  
Coord: Erin Palmer-Torrison  
PI: Dr. Chow  
Accrual: 8/67

UCI 25-75 (CRN09682-191):  
Crinetics Pharmaceuticals

Mechanism: NDC  
Coord: Michelle Andrade  
PI: Dr. Dayyani  
Accrual: 0/15

UCI 26-118 (YL211-INT-101-01)  
Y211 +/- Pembro

Mechanism: c-MET targeting  
ADC  
Coord: TBD  
PI: Dr. Arter  
Accrual: 0/5